RCKT
Rocket Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$3.43-0.29%
Price as of Jul 20, 2026
RCKT financials
Rocket Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $11.0M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$11.0M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $217.5M | $273.2M | $259.7M | $224.3M |
| Operating income | -$228.5M | -$273.2M | -$259.7M | -$224.3M |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M |
| EBITDA | -$210.2M | -$247.5M | -$236.6M | -$213.7M |
| Basic EPS | $-2.01 | $-2.73 | $-2.92 | $-3.26 |
| Diluted EPS | $-2.01 | $-2.73 | $-2.92 | $-3.26 |
| Balance sheet | ||||
| Cash & equivalents | $77.6M | $163.6M | $55.9M | $140.5M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M |
| Stockholders’ equity | $277.2M | $463.2M | $492.6M | $489.7M |
| Total debt | $24.9M | $25.5M | $25.0M | $22.9M |
| Net debt | -$52.7M | -$138.1M | -$30.9M | -$117.7M |
| Cash flow | ||||
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M |
| Capital expenditure | -$440.0K | -$5.9M | -$16.5M | -$8.6M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$67.0K | $0.00 | $0.00 | -$47.0K |